JSPR Overview

Briquilimab Study Results: Jasper Therapeutics released preliminary data from the ETESIAN Phase 1b study showing that a single 180mg dose of briquilimab significantly reduced sputum eosinophils and improved lung function indicators in adults with allergic asthma, demonstrating a favorable safety profile.

Eosinophil Reduction: Treatment with briquilimab led to substantial decreases in sputum eosinophil levels before and after allergen challenges, indicating its potential effectiveness in managing allergic asthma symptoms.

BEACON Cohort Investigation: Jasper completed an internal investigation into the lack of clinical response in the BEACON study cohorts, concluding that the unexpected results were likely due to patient selection issues rather than problems with the drug itself.

Stock Performance: Following the positive study results, Jasper Therapeutics' shares increased by 8.72%, reaching $1.87 at the time of publication.

Study Overview: Jasper Therapeutics reported positive preliminary data from its ETESIAN Phase 1b study of briquilimab for allergic asthma, showing significant reductions in sputum eosinophils and improvements in lung function.

Efficacy Results: A single dose of briquilimab resulted in notable improvements in FEV1 during both Early and Late Asthmatic Responses, along with significant reductions in serum tryptase levels.

Safety Profile: The treatment was well tolerated, indicating a favorable safety profile for briquilimab in the study participants.

Future Development: The encouraging results support the ongoing development of briquilimab as a potential new treatment option for asthma.

Jasper Therapeutics Webinar: Jasper Therapeutics Inc. will host a webinar on December 2, 2025, to present findings from its BEACON study on chronic spontaneous urticaria and preliminary data from the ETESIAN study on asthma.

BEACON Study Results: The BEACON trial, which evaluates Briquilimab for chronic spontaneous urticaria, reported that 89% of participants achieved a complete response with certain doses, and 73% maintained this response in an open-label extension.

ETESIAN Study Status: The ETESIAN study, focused on allergic asthma, was halted earlier this year due to a drug product lot issue, pausing further development in asthma.

Stock Performance: Jasper Therapeutics' stock closed at $1.72, down 6.52%, but saw a 16.27% increase in overnight trading, reaching $2 on the Nasdaq.